Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'- 18F-fluoropropyl)pyridine ( 18F-nifzetidine)

Department of Radiology, University of California-San Diego, CA, USA.
Nuclear Medicine and Biology (Impact Factor: 2.41). 08/2011; 38(8):1183-92. DOI: 10.1016/j.nucmedbio.2011.05.005
Source: PubMed


Thalamic and extrathalamic nicotinic α4β2 receptors found in the brain have been implicated in Alzheimer's disease, Parkinson's disease, substance abuse and other disorders. We report here the development of 3-(2-(S)-azetidinylmethoxy)-5-(3'-fluoropropyl)pyridine (nifzetidine) as a new putative high-affinity antagonist for nicotinic α4β2 receptors. Nifzetidine in rat brain homogenate assays containing α4β2 sites labeled with (3)H-cytisine exhibited a binding affinity: Ki=0.67 nM. The fluorine-18 analog, 3-(2-(S)-azetidinylmethoxy)-5-(3'-(18)F-fluoropropyl)pyridine ((18)F-nifzetidine), was synthesized in 20%-40% yield, and apparent specific activity was estimated to be above 2 Ci/μmol. Rat brain slices indicated selective binding of (18)F-nifzetidine to thalamus, subiculum, striata, cortex and other regions consistent with α4β2 receptor distribution. This selective binding was displaced >85% by 150 μM nicotine. Positron emission tomography (PET) imaging studies of (18)F-nifzetidine in anesthetized rhesus monkey showed slow uptake in the various brain regions. Retention of (18)F-nifzetidine was maximal in the thalamus and lateral geniculate followed by regions of the temporal and frontal cortex. Cerebellum showed the least uptake. Thalamus to cerebellum ratio was about 2.3 at 180 min postinjection and continued to rise. (18)F-Nifzetidine shows promise as a new PET imaging agent for α4β2 nAChR. However, the slow kinetics suggests a need for >3-h PET scans for quantitative studies of the α4β2 nAChRs.

Download full-text


Available from: Jogeshwar Mukherjee,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Imaging agents for nicotinic α4β2 receptors in the brain have been under way for studying various CNS disorders. Previous studies from our laboratories have reported the successful development of agonist, 18F-nifene. In attempts to develop potential antagonists, 18F-nifrolidine and 18F-nifzetidine were previously reported. Further optimization of these fluoropropyl derivatives has now been carried out resulting in 3-(2-(S)-3,4-dehydropyrrolinylmethoxy)-5-(3'-Fluoropropyl)pyridine (nifrolene) as a new high affinity agent for nicotinic α4β2 receptors. Nifrolene in rat brain homogenate assays - labeled with 3H-cytisine - exhibited a binding affinity of 0.36nM. The fluorine-18 analog, 18F-nifrolene, was synthesized in approximately 10%-20% yield and specific activity was estimated to be >2000Ci/mmol. Rat brain slices indicated selective binding to anterior thalamic nuclei, thalamus, subiculum, striata, cortex and other regions consistent with α4β2 receptor distribution. This selective binding was displaced >90% by 300μM nicotine. Thalamus to cerebellum ratio (>10) was the highest for 18F-nifrolene with several other regions showing selective binding. In vivo rat PET studies exhibited rapid uptake of 18F-nifrolene in the brain with specific retention in the thalamus and other brain regions while clearing out from the cerebellum. Thalamus to cerebellum ratio value in the rat was >4. Administration of nicotine caused a rapid decline in the thalamic 18F-nifrolene suggesting reversible binding to nicotinic receptors. PET imaging studies of 18F-nifrolene in anesthetized rhesus monkey revealed highest binding in the thalamus followed by regions of the lateral cingulated and temporal cortex. Cerebellum showed the least binding. Thalamus to cerebellum ratio in the monkey brain was >3 at 120min. These ratios of 18F-nifrolene are higher than measured for 18F-nifrolidine and 18F-nifzetidine. 18F-Nifrolene thus shows promise as a new PET imaging agent for α4β2 nAChR.
    Nuclear Medicine and Biology 11/2012; 40(1). DOI:10.1016/j.nucmedbio.2012.09.009 · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral neuronal nicotinic acetylcholine receptors (nAChRs) are implicated in various neurophysiological processes and in the pathophysiology and/or treatment strategies of various disorders. Positron emission tomography (PET) imaging of nAChR and, especially, the most prominent cerebral subtype α4β2-nAChR is important in smoking, epilepsy, attention deficit hyperactivity disorder, depression, schizophrenia, cognition, behavior, memory, and in research involving aging, cognitive impairments, and dementia. Most human α4β2-nAChR PET imaging has been performed with 2-[18F]FA, but slow brain kinetics is the substantial drawback of 2-[18F]FA that precludes widespread PET imaging research of nAChR in humans. Development of a better PET radioligand for α4β2-nAChR was a focus of substantial investigation that has been thoroughly reviewed (up to 2009) previously. This article attempts to summarize the peer-reviewed publications of the most recent development and preclinical studies of novel α4β2-nAChR PET radioligands with improved brain kinetics and first human studies with one of these radioligands ([18F]AZAN).
    Journal of Labelled Compounds 03/2013; 56(3-4):159-166. DOI:10.1002/jlcr.3020 · 1.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The aims of the present study were to develop an optimized microfluidic method for the production of the selective nicotinic acetylcholine α4β2 receptor radiotracer [18 F]-(−)-NCFHEB ([18 F]-Flubatine) and to investigate its receptor binding profile and pharmacokinetic properties in rhesus monkeys in vivo. Methods 18 F-(-)-NCFHEB was prepared in two steps, a nucleophilic fluorination followed by N-Boc deprotection. PET measurements were performed in rhesus monkeys including baseline and preblocking experiments with nicotine (0.24 mg/kg). Radiometabolites in plasma were measured using HPLC. Results 18 F]-(−)-NCFHEB was prepared in a total synthesis time of 140 min. The radiochemical purity in its final formulation was > 98% and the mean specific radioactivity was 97.3 ± 16.1 Bq/ μmol (n = 6) at end of synthesis (EOS). In the monkey brain, radioactivity concentration was high in the thalamus, moderate in the putamen, hippocampus, frontal cortex, and lower in the cerebellum. Nicotine blocked 98-100% of [18 F]-(-)-NCFHEB specific binding, and the non-displaceable distribution volume (VND) was estimated at 5.9 ± 1.0 mL/cm3 (n = 2), or 6.6 ± 1.1 mL/cm3 after normalization by the plasma free fraction fP. Imaging data are amenable to kinetic modeling analysis using the multilinear analysis (MA1) method, and model-derived binding parameters display good test-retest reproducibility. In rhesus monkeys, [18 F-(-)-NCFHEB can yield robust regional binding potential (BPND) values (thalamus = 4.1 ± 1.5 frontal cortex = 1.2 ± 0.2 putamen = 0.96 ± 0.45 cerebellum = 0.10 ± 0.29) Conclusion An efficient microfluidic synthetic method was developed for preparation of [18 F]-(−)-NCFHEB. PET examination in rhesus monkeys showed that [18 F]-(−)-NCFHEB entered the brain readily and its regional radioactivity uptake pattern was in accordance with the known distribution of α4β2 receptors. Estimated non-displaceable binding potential (BPND) values in brain regions were better than those of [18 F]-2FA and comparable to [18 F]-AZAN. These results confirm previous findings and support further examination of [18 F]-(−)-NCFHEB in humans.
    Nuclear Medicine and Biology 08/2014; 42(6). DOI:10.1016/j.nucmedbio.2014.08.003 · 2.41 Impact Factor
Show more

Similar Publications